Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaginal treatment aims to clear Cancer-Causing HPV virus

NCT ID NCT06491446

Ongoing Disease control Sponsor: Antiva Biosciences Source: ClinicalTrials.gov ↗

Summary

This study is testing a vaginal insert called ABI-2280 to see if it can safely clear persistent, high-risk HPV infections in women. About 141 women aged 25-55 with a long-term HPV infection will receive either the active insert or a placebo. The main goal is to see if the treatment can eliminate the virus and is safe to use.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Arke Estudios Clinicos S.A. De C.V.

    Cuauhtémoc, CP 06700, Mexico

  • AusTrials Taringa

    Taringa, Australia

  • AusTrials Wellers Hill

    Tarragindi, Australia

  • Centro Oncologico Internacional

    Mexico City, CP 04700, Mexico

  • Clinical Horizons New Zealand

    Tauranga, New Zealand

  • Emeritus Research Camberwell

    Camberwell, Australia

  • Emeritus Research Sydney

    Sydney, Australia

  • FAICIC S. de R.L. de C.V.

    Veracruz, CP 91900, Mexico

  • Holdsworth House Medical Practice

    Darlinghurst, Australia

  • International Cancer Institute

    Eldoret, 8088-30100, Kenya

  • KIMR

    Nedlands, Australia

  • Kenya Medical Research Institute (KEMRI) - RCTP Kisumu

    Kisumu, 614-40100, Kenya

  • Lakeland Clinical Trials

    Rotorua, New Zealand

  • P3 Research Dunedin

    Dunedin, New Zealand

  • P3 Research Hawke's Bay

    Hastings, New Zealand

  • P3 Research Kapiti

    Paraparaumu, New Zealand

  • P3 Research Lower Hutt

    Lower Hutt, New Zealand

  • PARC Clinical Research, Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Pacific Clinical Trials Network - Tasman

    Nelson, New Zealand

  • The Royal Women's Hospital

    Parkville, Australia

  • Unidad de Medicina Especializada SMA

    Querétaro, CP 76800, Mexico

  • Victoria Biomedical Research Institute

    Kisumu, 7180-40100, Kenya

  • Victoria Cancer Care & Research Centres

    Kisii, 1376-40500, Kenya

  • Waitemata Clinical Research Ltd

    Birkenhead, New Zealand

Conditions

Explore the condition pages connected to this study.

HUMAN PAPILLOMAVIRUS INFECTION